查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物傳輸市場到2030年的預測：按類型、容量、配銷通路、應用和區域進行的全球分析
市場調查報告書
商品編碼
1383356

藥物傳輸市場到2030年的預測：按類型、容量、配銷通路、應用和區域進行的全球分析

Drug Delivery Market Forecasts to 2030 - Global Analysis By Type, Capacity, Distribution Channel, Application and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球給藥市場規模將達到202 億美元，預計到2030年將達到 355 億美元，預測期內年複合成長率為 8.4%。

藥物傳輸是指以受管制和有針對性的方式將藥物或治療劑等藥用物質給藥到人體的過程。提高藥物治療效果、減少副作用、提高患者依從性非常重要。它們在提高醫療保健和患者照護的整體品質方面發揮著重要作用。

根據美國心臟協會統計，2019年全球有1億015億中風患者。缺血性中風7720萬例，腦出血2070萬例，蜘蛛膜下腔出血840萬例。

精準醫療的興起

精準醫學根據個體的遺傳、基因組和生理特徵量身訂做醫療治療，包括藥物治療。這種方法需要精確的藥物輸送系統，能夠高精度地針對特定的分子途徑和細胞。因此，藥物傳輸技術不斷發展以滿足個人化醫療的需求，允許在體內的特定時間和位置給藥精確的給藥。這確保了正確的治療到達正確的患者，最大限度地提高治療效果，同時最大限度地減少副作用。

開發成本高

新的藥物輸送技術的研究和開發，從改進的配方到先進的輸送系統，在經濟上是負擔重的。這些成本包括臨床前研究、臨床試驗、監管核准、製造流程等。最先進的藥物傳輸系統所需的複雜性和創新進一步推高了成本。此外，高昂的開發成本會阻礙中小企業進入市場並減慢創新步伐。這將需要大量的財務投資，公司面臨的挑戰是如何將具有成本效益的解決方案推向市場，並最終將影響先進藥物輸送方法的可及性和可負擔性。

遠端醫療和遠端監控的成長

遠端醫療和遠端患者監護的成長為藥物輸送市場帶來了巨大的機會。遠端醫療的普及使患者能夠在自己舒適的家中接受醫療服務，減少了親自到診所就診的需要。這種向遠端醫療的轉變創造對創新藥物輸送系統的需求，這些系統使患者能夠在遠端醫療監督下有效、安全地自行給藥。無論是管理慢性疾病或提供關鍵治療方法，這些遠距藥物傳輸解決方案都可以提高患者的依從性、治療結果和整體醫療保健效率。隨著遠端醫療的持續發展，藥物傳輸市場將需要開發和提供以患者為中心的新技術，以適應不斷發展的醫療傳遞環境，並最終提高藥物治療的可及性和有效性。

網路安全風險

網路安全風險對藥物輸送市場構成越來越大的威脅。隨著藥物輸送系統變得更加互聯並且更加依賴數位技術，它們變得更容易受到網路攻擊。惡意行為者可能會損害這些系統的安全性和功能，危及病人安全和藥物給藥的完整性。此類攻擊可能會導致劑量不正確、未經授權存取患者資料或系統故障。確保這些設備的網路安全勢在必行，因為違規可能會造成嚴重後果，並損害患者的信任和行業聲譽。

COVID-19 的影響

由於住院人數減少，供應鏈中斷和製造業暫時停頓等因素，COVID-19 的爆發擾亂了世界各地醫療保健產業的工作流程。這種疾病迫使許多行業暫時關閉，包括醫療保健的幾個子領域。疫情期間，由於藥品供應中斷，全球給藥市場受到中度影響。然而，隨著COVID-19疫苗的推出和大規模疫苗接種運動，製造商顯著加快了注射給藥系統的生產，以滿足全球醫療需求。由於醫院就診人數的增加和先進給藥系統的推出，預計疫情後市場將大幅成長。

植入式藥物傳輸領域預計將成為預測期內最大的領域

植入式藥物傳輸領域估計佔最大佔有率。植入式藥物傳輸是藥物傳輸市場的一個專門領域，包括使用目的是將藥物直接輸送到體內以進行受控和緩釋性的醫療設備。這些裝置通常植入皮下或某些身體組織內，可以長時間給藥藥物，減少頻繁給藥的需要。植入式藥物傳輸系統可用於多種醫療應用，包括糖尿病等慢性疾病的治療和疼痛管理，為患者提供便利性並改善治療結果，同時最大限度地減少潛在的副作用。該領域是提高藥物療效和患者依從性的創新方法。

預計心血管疾病在預測期內的年複合成長率最高

預計心血管疾病領域在預測期內將出現良好的成長。心血管疾病（CVD）是藥物輸送市場的一個重要且多方面的區隔。該領域致力於開發創新的藥物傳輸系統和治療方法，以預防、管理和治療高血壓、冠狀動脈疾病、心臟衰竭、中風等。 CVD 藥物傳輸技術包括多種解決方案，包括控制釋放製劑、防止動脈阻塞的藥物塗層支架以及抗凝血劑和抗血小板藥物的新型輸送方法。這些進步提高了藥物療效，提高了患者的依從性，並降低了不利事件的風險。此外，由於心血管疾病是全球死亡的主要原因，心血管藥物輸送市場有望透過提供有助於更好的結果和整體心血管健康的解決方案來緩解這一公共衛生危機。

佔有率最大的地區

在估計期間，亞太地區佔據最大的市場佔有率。該地區市場擴張的主要原因是癌症發病率的上升以及公眾對癌症治療知識的不斷增加。亞太地區人口眾多，近年來，由於生活方式的改變、環境因素和人口高齡化，癌症發生率呈上升趨勢。因此，接受治療的患者數量不斷增加，藥品分發的需求也不斷增加。此外，可支配所得不斷增加且市場參與企業俱有良好潛力的亞太地區預計將在預測期內呈現最高成長率。此外，印度製造商提高產能，以滿足對注射器不斷成長的需求，推動全部區域的市場成長。

年複合成長率最高的地區：

預計北美在預測期內將實現盈利成長。這是由於糖尿病、癌症和呼吸道過敏等慢性疾病的增加、患者對新給藥技術的醫囑遵從性提高以及該地區名人的高度集中。隨著許多主要企業進入這一領域，市場不斷擴大，包括諾華公司、輝瑞公司、霍夫曼拉羅氏有限公司和默克公司。此外，隨著生物製藥產業開發出大量可治療多種非傳染性疾病的新藥，北美對藥物傳輸解決方案的需求迅速增加。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球藥物輸送市場：依類型

  • 介紹
  • 注射給藥
  • 經皮經皮
  • 口服給藥
  • 局部給藥
  • 粘膜給藥
  • 植入式藥物輸送
  • 眼科藥物輸送
  • 其他類型

第6章 全球藥物傳輸市場：依設備類型

  • 介紹
  • 高級型
  • 傳統型

第7章 全球藥物輸送市場：依配銷通路

  • 介紹
  • 零售藥房
  • 醫院藥房
  • 線上藥房
  • 其他配銷通路

第8章 全球藥物傳輸市場：依應用分類

  • 介紹
  • 瘤
  • 心血管疾病
  • 糖尿病
  • 中樞神經系統疾病
  • 呼吸系統疾病
  • 其他用途

第9章 全球藥物輸送市場：依最終用戶分類

  • 介紹
  • 居家醫療
  • 醫院和診所
  • 門診手術中心
  • 其他最終用戶

第10章 全球藥物輸送市場：依地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Abbott
  • Bayer
  • AstraZeneca
  • Sanofi
  • GlaxoSmithKline
  • La Roche
  • Johnson & Johnson
  • Novartis AG
  • Merck
  • Pfizer
  • Antares Pharma
  • GSK
  • Accord Healthcare
  • Becton Dickinson and Co
  • Boston Scientific Corp
  • Baxter International Inc
  • Kindeva Drug Delivery LP
  • Gerresheimer AG
  • Sever Pharma Solutions
  • Boehringer Ingelheim International
Product Code: SMRC24206

According to Stratistics MRC, the Global Drug Delivery Market is accounted for $20.2 billion in 2023 and is expected to reach $35.5 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Drug delivery refers to the process of administering pharmaceutical substances, such as drugs or therapeutic agents, to the human body in a controlled and targeted manner. It is essential for improving the therapeutic impact of pharmaceuticals, reducing side effects, and enhancing patient compliance. It plays a critical role in advancing medical treatments and the overall quality of patient care.

According to the American Heart Association, 101.5 million stroke cases worldwide in 2019. Ischemic stroke cases were 77.2 million, intracerebral hemorrhage cases were 20.7 million, and subarachnoid hemorrhage cases were 8.4 million.

Market Dynamics:

Driver:

Rise in precision medicine

Precision medicine tailors medical treatments, including drug therapies, to an individual's unique genetic, genomic, and physiological characteristics. This approach demands precise drug delivery systems that can target specific molecular pathways or cells with high accuracy. As a result, drug delivery technologies have evolved to accommodate the requirements of personalised medicine, enabling the administration of precise dosages at specific times and locations in the body. This ensures that the right treatment reaches the right patient, maximising therapeutic effectiveness while minimising side effects.

Restraint:

High development costs

Researching and developing new drug delivery technologies, from formulation enhancements to advanced delivery systems, can be a financial burden. These costs encompass pre-clinical testing, clinical trials, regulatory approvals, and manufacturing processes. The complexity and innovation required for cutting-edge drug delivery systems further drive up expenses. Moreover, these high development costs can deter smaller companies from entering the market and may slow down the pace of innovation. It necessitates substantial financial investments and makes it challenging for companies to bring cost-effective solutions to market, ultimately affecting the accessibility and affordability of advanced drug delivery methods.

Opportunity:

Growth of telemedicine and remote monitoring

The growth of telemedicine and remote patient monitoring presents a substantial opportunity for the drug delivery market. Telehealth's expanding popularity allows patients to access healthcare services from the comfort of their homes, reducing the need for in-person clinic visits. This shift towards remote care creates a demand for innovative drug delivery systems that enable patients to self-administer medications effectively and safely under remote medical supervision. Whether it's managing chronic conditions or delivering critical therapies, these remote drug delivery solutions can improve patient compliance, treatment outcomes, and overall healthcare efficiency. As telemedicine continues to gain momentum, the drug delivery market has the potential to develop and offer new, patient-centric technologies that align with the evolving landscape of healthcare delivery, ultimately enhancing the accessibility and effectiveness of drug treatments.

Threat:

Cybersecurity risks

Cybersecurity risks represent a growing threat to the drug delivery market. As drug delivery systems become increasingly interconnected and reliant on digital technologies, they become susceptible to cyber attacks. Malicious actors could potentially compromise the security and functionality of these systems, endangering patient safety and the integrity of drug administration. Such attacks may lead to incorrect dosing, unauthorised access to patient data, or system failures. Ensuring the cybersecurity of these devices is imperative, as breaches can have severe consequences, eroding patient trust and industry reputation.

COVID-19 Impact

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world due to factors such as reduced hospital admissions, disruptions in the supply chain, temporary halts in manufacturing, and others across the globe. The disease has forced a number of industries to temporarily shut their doors, including several sub-domains of health care. The global pharmaceutical drug delivery market was moderately impacted during the pandemic due to disruptions in the supply of pharmaceutical products. However, with the launch of COVID-19 vaccines and mass vaccination drives, there was a significant acceleration in manufacturers' production of injectable drug delivery systems to meet global medical needs. The market in the post-pandemic period will grow significantly due to increased hospital visits and the launch of advanced drug delivery systems, among others.

The Implantable Drug Delivery segment is expected to be the largest during the forecast period

The Implantable Drug Delivery segment is estimated to hold the largest share. Implantable drug delivery is a specialised segment of the drug delivery market that involves the use of medical devices designed to deliver pharmaceutical agents directly into the body for controlled and sustained release. These devices, often implanted under the skin or within specific bodily tissues, can administer drugs over extended periods, reducing the need for frequent dosing. Implantable drug delivery systems are used in various medical applications, including the treatment of chronic conditions such as diabetes and pain management, offering patients convenience and improved therapeutic outcomes while minimising potential side effects. This segment represents an innovative approach to enhancing drug efficacy and patient compliance.

The Cardiovascular Diseases segment is expected to have the highest CAGR during the forecast period

The Cardiovascular Diseases segment is anticipated to have lucrative growth during the forecast period. Cardiovascular diseases (CVD) represent a significant and multifaceted segment within the drug delivery market. This sector is dedicated to developing innovative drug delivery systems and therapies aimed at preventing, managing, and treating conditions such as hypertension, coronary artery disease, heart failure, and stroke. Drug delivery technologies for CVD encompass a wide range of solutions, including controlled-release formulations, stents coated with medications to prevent artery blockage, and novel delivery methods for anticoagulants and antiplatelet agents. These advancements improve the efficacy of medications, enhance patient compliance, and reduce the risk of adverse cardiovascular events. Moreover, with CVD being a leading cause of mortality worldwide, the cardiovascular drug delivery market plays a pivotal role in mitigating this public health crisis by providing solutions that contribute to better outcomes and overall cardiovascular health.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The rising incidence of cancer and growing public knowledge of cancer treatments are the main causes of this region's market expansion. With a vast population, the Asia-Pacific region has experienced an increase in cancer prevalence in recent years as a result of changing lifestyles, environmental factors, and ageing populations. As a result, there are an increasing number of patients receiving treatment, which raises the need for the distribution of pharmaceutical drugs. Moreover, due to the increase in disposable income as well as the lucrative potential for major participants in the market, Asia-Pacific is expected to develop at the highest rate during the forecast period. Furthermore, manufacturers in India are increasing their production capacities to meet the rising demand for syringes, thereby fostering overall market growth across the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. This is attributed to several factors, including the increased occurrence of chronic illnesses including diabetes, cancer, and respiratory allergies; increased patient adherence to novel drug delivery technology; and the concentration of notable individuals in this area. The market is expanding due to the presence of many significant players, including Novartis AG, Pfizer Inc., F. Hoffmann La-Roche Ltd., and Merck and Co., Inc., in the area. Moreover, the need for pharmaceutical drug delivery solutions in North America is growing rapidly due to the biopharmaceutical industry's development of numerous novel medications that can cure a range of non-communicable disorders.

Key players in the market

Some of the key players in the Drug Delivery Market include: Abbott, Bayer, AstraZeneca, Sanofi, GlaxoSmithKline, La Roche, Johnson & Johnson, Novartis AG, Merck, Pfizer, Antares Pharma, GSK, Accord Healthcare, Becton Dickinson and Co, Boston Scientific Corp, Baxter International Inc, Kindeva Drug Delivery LP, Gerresheimer AG, Sever Pharma Solutions and Boehringer Ingelheim International.

Key Developments:

In December 2022, Johnson & Johnson announced the launch of its ACUITY™ MRI SureScan™ pacemaker. This pacemaker is the first and only MRI-conditional pacemaker that is also compatible with Johnson & Johnson's ACUITY™ MRI SureScan™ defibrillator.

In November 2022, Sorin Group announced the launch of its Evia™ leadless pacemaker. This pacemaker is a small, wireless device that is implanted directly into the heart without the need for leads.

In October 2022, Arena Pharmaceuticals announced the approval of its drug, ravulizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ravulizumab is a long-acting, subcutaneously administered C5 complement inhibitor that provides sustained protection from hemolysis in patients with PNH.

In September 2022, Alnylam Pharmaceuticals announced the approval of its drug, vutrisiran, for the treatment of hereditary transthyretin amyloidosis (ATTR amyloidosis). Vutrisiran is a subcutaneously administered RNA interference (RNAi) therapy that targets the production of TTR protein.

In August 2022, Sanofi announced the approval of its drug, Dupixent, for the treatment of atopic dermatitis in adults and children aged 6 years and older. Dupixent is a human monoclonal antibody that targets the IL-4 and IL-13 cytokines.

Types Covered:

  • Injectable Drug Delivery
  • Transdermal Drug Delivery
  • Oral Drug Delivery
  • Topical Drug Delivery
  • Transmucosal Drug Delivery
  • Implantable Drug Delivery
  • Ocular Drug Delivery
  • Other Types

Device Types Covered:

  • Advanced
  • Conventional

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Applications Covered:

  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Central Nervous System Disorders
  • Respiratory Diseases
  • Other Applications

End Users Covered:

  • Home Care Settings
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Delivery Market, By Type

  • 5.1 Introduction
  • 5.3 Injectable Drug Delivery
  • 5.4 Transdermal Drug Delivery
  • 5.5 Oral Drug Delivery
  • 5.6 Topical Drug Delivery
  • 5.7 Transmucosal Drug Delivery
  • 5.8 Implantable Drug Delivery
  • 5.9 Ocular Drug Delivery
  • 5.1 Other Types

6 Global Drug Delivery Market, By Device Type

  • 6.1 Introduction
  • 6.2 Advanced
  • 6.3 Conventional

7 Global Drug Delivery Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Hospital Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Other Distribution Channels

8 Global Drug Delivery Market, By Application

  • 8.1 Introduction
  • 8.2 Oncology
  • 8.3 Cardiovascular Diseases
  • 8.4 Diabetes
  • 8.5 Central Nervous System Disorders
  • 8.6 Respiratory Diseases
  • 8.7 Other Applications

9 Global Drug Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Home Care Settings
  • 9.3 Hospitals and Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Other End Users

10 Global Drug Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott
  • 12.2 Bayer
  • 12.3 AstraZeneca
  • 12.4 Sanofi
  • 12.5 GlaxoSmithKline
  • 12.6 La Roche
  • 12.7 Johnson & Johnson
  • 12.8 Novartis AG
  • 12.9 Merck
  • 12.10 Pfizer
  • 12.11 Antares Pharma
  • 12.12 GSK
  • 12.13 Accord Healthcare
  • 12.14 Becton Dickinson and Co
  • 12.15 Boston Scientific Corp
  • 12.16 Baxter International Inc
  • 12.17 Kindeva Drug Delivery LP
  • 12.18 Gerresheimer AG
  • 12.19 Sever Pharma Solutions
  • 12.20 Boehringer Ingelheim International

List of Tables

  • Table 1 Global Drug Delivery Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Drug Delivery Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Drug Delivery Market Outlook, By Injectable Drug Delivery (2021-2030) ($MN)
  • Table 4 Global Drug Delivery Market Outlook, By Transdermal Drug Delivery (2021-2030) ($MN)
  • Table 5 Global Drug Delivery Market Outlook, By Oral Drug Delivery (2021-2030) ($MN)
  • Table 6 Global Drug Delivery Market Outlook, By Topical Drug Delivery (2021-2030) ($MN)
  • Table 7 Global Drug Delivery Market Outlook, By Transmucosal Drug Delivery (2021-2030) ($MN)
  • Table 8 Global Drug Delivery Market Outlook, By Implantable Drug Delivery (2021-2030) ($MN)
  • Table 9 Global Drug Delivery Market Outlook, By Ocular Drug Delivery (2021-2030) ($MN)
  • Table 10 Global Drug Delivery Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Drug Delivery Market Outlook, By Device Type (2021-2030) ($MN)
  • Table 12 Global Drug Delivery Market Outlook, By Advanced (2021-2030) ($MN)
  • Table 13 Global Drug Delivery Market Outlook, By Conventional (2021-2030) ($MN)
  • Table 14 Global Drug Delivery Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 15 Global Drug Delivery Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 16 Global Drug Delivery Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 17 Global Drug Delivery Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 18 Global Drug Delivery Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 19 Global Drug Delivery Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Drug Delivery Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 21 Global Drug Delivery Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 22 Global Drug Delivery Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 23 Global Drug Delivery Market Outlook, By Central Nervous System Disorders (2021-2030) ($MN)
  • Table 24 Global Drug Delivery Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 25 Global Drug Delivery Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 26 Global Drug Delivery Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Drug Delivery Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 28 Global Drug Delivery Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 29 Global Drug Delivery Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 30 Global Drug Delivery Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.